ESMO 2022 | Kidney cancer at ESMO 2022: KEYNOTE-564 and PROSPER

Ramaprasad Srinivasan, MD, PhD, National Cancer Institute, Bethesda, MD, talks on his highlights in kidney cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress, including findings from the Phase III KEYNOTE-564 (NCT03142334), which assessed adjuvant pembrolizumab in renal cell carcinoma (RCC), as well as results from the Phase III PROSPER trial (NCT03055013) of perioperative nivolumab in RCC. Dr Srinivasan additionally discusses the use of telisotuzumab in RCC. This interview took place at the ESMO 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.